These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11839068)

  • 1. Whole-body FDG-PET imaging in the management of patients with cancer.
    Hustinx R; Bénard F; Alavi A
    Semin Nucl Med; 2002 Jan; 32(1):35-46. PubMed ID: 11839068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography imaging in evaluation of cancer patients.
    Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
    Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.
    Dizendorf EV; Baumert BG; von Schulthess GK; Lütolf UM; Steinert HC
    J Nucl Med; 2003 Jan; 44(1):24-9. PubMed ID: 12515872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
    Zuijdwijk MD; Vogel WV; Corstens FH; Oyen WJ
    Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET and alternative imaging in the management of thyroid carcinoma.
    Al-Nahhas AM
    Nucl Med Rev Cent East Eur; 2003; 6(2):139-45. PubMed ID: 14737730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.
    Scanga DR; Martin WH; Delbeke D
    Clin Nucl Med; 2004 Feb; 29(2):86-90. PubMed ID: 14734903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.
    Hicks RJ; Kalff V; MacManus MP; Ware RE; McKenzie AF; Matthews JP; Ball DL
    J Nucl Med; 2001 Nov; 42(11):1605-13. PubMed ID: 11696628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
    Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
    J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
    Reske SN; Kotzerke J
    Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET in the follow-up of differentiated thyroid cancer.
    Khan N; Oriuchi N; Higuchi T; Zhang H; Endo K
    Br J Radiol; 2003 Oct; 76(910):690-5. PubMed ID: 14512328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.
    Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Lin KJ; Lin WJ; Fu YK; Lin CY
    J Nucl Med; 2005 Mar; 46(3):405-10. PubMed ID: 15750151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.